Posted on April 26th, 2012, 9:53 pm
Medscape âThis approval underscores the FDA's commitment to the development of drugs for rare diseases with significant unmet medical needs,â said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug ... |